RTP Mobile Logo
Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Breast Cancer (Faculty Presentations)
Released April 2021

Featuring slide presentations and related discussion from Drs Harold J Burstein and Lisa Carey. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

    LEARNING OBJECTIVES

    • Evaluate published research data to guide the selection and duration of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
    • Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer, incorporating existing and recently approved anti-HER2 therapies.
    • Recognize common and rare side effects associated with novel anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
    • Evaluate the results of genomic assays and other relevant patient- and treatment-related factors to personalize the use of adjuvant systemic therapy in newly diagnosed ER-positive breast cancer.
    • Individualize the selection and sequence of systemic therapy for patients with ER-positive metastatic breast cancer, considering age, menopausal status, prior treatment course, comorbidities, symptomatology and extent and sites of disease.
    • Review published research data supporting the benefit of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for patients with newly diagnosed PD-L1-positive metastatic triple-negative breast cancer (mTNBC), and use this information to make treatment recommendations.
    • Recall available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for patients with localized TNBC, and determine the current and potential role of these strategies in clinical practice.
    • Assess potential biomarkers of response to PARP inhibition, and use this information to optimize the selection of available genetic testing platforms and related therapeutic interventions for patients with metastatic breast cancer.
    • Appraise recent FDA approvals and ongoing clinical research of novel agents and treatment strategies for various forms of breast cancer, and counsel patients about protocol and nonresearch treatment recommendations.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Harold J Burstein, MD, PhD
    Institute Physician, Dana-Farber Cancer Institute
    Professor of Medicine, Harvard Medical School
    Boston, Massachusetts

    No financial interests or affiliations to disclose.

    Lisa Carey, MD
    Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research
    Deputy Director of Clinical Sciences
    Lineberger Comprehensive Cancer Center
    University of North Carolina
    Chapel Hill, North Carolina

    No financial interests or affiliations to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Novartis, Puma Biotechnology Inc and Seagen Inc.

    Release date: April 2021
    Expiration date: April 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):